Page 81 - MEMORIA ANUAL 2021
P. 81

   MEMORIA ANUAL 2021 SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
PETHEMA
FUNDACIÓN ESPAÑOLA DE HEMATOLOGÍA Y HEMOTERAPIA
  S, Maluquer C, Coll R, González-Campos J, Tormo M, García-Cadenas I, Nomdedéu J, Gil C, Cervera M, Escoda L, Montesinos P, Barba P, Esteve J, Díaz-Beyá M, Martínez-Sánchez P, Martínez-López J, Novo A, Queipo MP, Bermúdez A, Bergua J, Olave MT, De Rueda B, Artola MT, Hernández-Rivas JM, Orfao A, Ribera JM .
• Survival of Patients with Acute Myeloid Leukemia According to Age in a University Hospital in Colombia.
Clin Lymphoma Myeloma Leuk. Sep 2021;21(Suppl. 1):S312-S3. Abstract: AML-447. Sossa Melo CL, Ortiz MF, Salazar LA, Peña AM, Jiménez SI, Rosales M, Luna-González ML, Vásquez D, Ochoa M, Sanz Alonso M, Montesinos P .
• Survival of Patients with Secondary Acute Myeloid Leukemia in a University Hospital in Colombia.
Clin Lymphoma Myeloma Leuk. Sep 2021;21(Suppl. 1):S311-S2. Poster: AML-437.
Ortiz MF, Pena AM, Salazar LA, Jiménez SI, Rosales M, Luna-González M, Vásquez D, Ochoa M, Chen X, Sanz Alonso M, Montesinos P, Sossa C .
• Azacitidine or Decitabine Monotherapy for the Treatment of AML: A Comparative Systematic Review and Meta-Analysis.
Clin Lymphoma Myeloma Leuk. Sep 2021;21(Suppl. 1):S296-S. Poster: AML-266. Saiz-Rodríguez M, Labrador J, Cuevas B, Martínez-Cuadrón D, Campuzano V, Alcaraz R, Cano I, Sanz MA, Montesinos P .
• Real-Life Evidence of Treatment with Venetoclax in Patients with Relapsed or Re- fractory Acute Myeloid Leukemia.
Clin Lymphoma Myeloma Leuk. Sep 2021;21(Suppl. 1):S306-S. Poster: AML-331. Saiz-Rodríguez M, Labrador J, Martínez-Cuadrón D, Sanz MA, Montesinos P; PETHEMA Group .
• Acute Myeloid Leukemia: A Multicenter Experience in Colombia, on behalf of ACHO’s RENEHOC Investigators.
Clin Lymphoma Myeloma Leuk. Sep 2021;21(Suppl. 1):S310-S1. Poster: AML-425.
Sossa C, Polo VA, Salazar LA, Rosales M, Idrobo H, Reyes-Castellanos J, Mantilla W, Quin- tero G, Gómez R, Peña AM, Sanz Alonso M, Montesinos P .
• Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.
J Clin Oncol. 2021;39(15). 2021 ASCO Annual Meeting.
 81
 














































































   79   80   81   82   83